Undervalued Dividend Growth Stock of the Week: Pfizer Inc. (PFE)
This stock offers a utility-like yield but with far greater growth potential. Plus, it’s potentially 8% undervalued right now…
Read MorePosted by Jason Fieber, Dividends And Income | Feb 12, 2017
This stock offers a utility-like yield but with far greater growth potential. Plus, it’s potentially 8% undervalued right now…
Read MorePosted by Jason Fieber, Dividends And Income | Feb 6, 2017
A thoughtful approach to spending has been a key component that allowed me to retire in six years on a $50k salary — going from below broke at 27 years old to retired at 33. This is the final installment in a five-part series that discusses five real-life changes I’ve made over the years…
Read MorePosted by Jason Fieber, Dividends And Income | Feb 5, 2017
With shares potentially 17% undervalued right now, on top of huge dividend growth and a yield that’s well above its recent historical average, this stock looks like a great idea for long-term dividend growth investors…
Read MorePosted by Jason Fieber, Dividends And Income | Jan 29, 2017
This is a prototypical dividend growth stock with 54 consecutive years of dividend increases under its belt. And based on the company’s dominant industry position, scale, brand name, and pricing power, I don’t see those increases stopping. With shares potentially 7% undervalued right now, on top of a yield that’s well above recent historical averages, this could be an opportunity to invest in a high-quality company at an appealing valuation…
Read MorePosted by Jason Fieber, Dividends And Income | Jan 28, 2017
A thoughtful approach to spending has been a key component that allowed me to retire in six years on a $50k salary — going from below broke at 27 years old to retired at 33. This is the fourth installment in a five-part series that discusses five real-life changes I’ve made over the years to my own spending that can be replicated by anyone…
Read More